207 related articles for article (PubMed ID: 31049551)
1. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.
Jacqz-Aigrain E; Leroux S; Thomson AH; Allegaert K; Capparelli EV; Biran V; Simon N; Meibohm B; Lo YL; Marques R; Peris JE; Lutsar I; Saito J; Nakamura H; van den Anker JN; Sharland M; Zhao W
J Antimicrob Chemother; 2019 Aug; 74(8):2128-2138. PubMed ID: 31049551
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
[TBL] [Abstract][Full Text] [Related]
3. Association between vancomycin trough concentration and area under the concentration-time curve in neonates.
Frymoyer A; Hersh AL; El-Komy MH; Gaskari S; Su F; Drover DR; Van Meurs K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6454-61. PubMed ID: 25136027
[TBL] [Abstract][Full Text] [Related]
4. An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.
Hill LF; Turner MA; Lutsar I; Heath PT; Hardy P; Linsell L; Jacqz-Aigrain E; Roilides E; Sharland M;
Trials; 2020 Apr; 21(1):329. PubMed ID: 32293527
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.
Mulubwa M; Griesel HA; Mugabo P; Dippenaar R; van Wyk L
Drugs R D; 2020 Jun; 20(2):105-113. PubMed ID: 32266599
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
7. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data.
Germovsek E; Osborne L; Gunaratnam F; Lounis SA; Busquets FB; Standing JF; Sinha AK
J Antimicrob Chemother; 2019 Apr; 74(4):1003-1011. PubMed ID: 30668696
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
Lo YL; van Hasselt JG; Heng SC; Lim CT; Lee TC; Charles BG
Antimicrob Agents Chemother; 2010 Jun; 54(6):2626-32. PubMed ID: 20385872
[TBL] [Abstract][Full Text] [Related]
9. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
[TBL] [Abstract][Full Text] [Related]
10. Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.
Kim J; Walker SA; Iaboni DC; Walker SE; Elligsen M; Dunn MS; Allen VG; Simor A
Antimicrob Agents Chemother; 2014 May; 58(5):2830-40. PubMed ID: 24614381
[TBL] [Abstract][Full Text] [Related]
11. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
[TBL] [Abstract][Full Text] [Related]
12. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.
Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM
Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.
Marqués-Miñana MR; Saadeddin A; Peris JE
Br J Clin Pharmacol; 2010 Nov; 70(5):713-20. PubMed ID: 21039765
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Zhao W; Hill H; Le Guellec C; Neal T; Mahoney S; Paulus S; Castellan C; Kassai B; van den Anker JN; Kearns GL; Turner MA; Jacqz-Aigrain E;
Antimicrob Agents Chemother; 2014 Nov; 58(11):6572-80. PubMed ID: 25155587
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and dose optimization of vancomycin in neonates.
Lee SM; Yang S; Kang S; Chang MJ
Sci Rep; 2021 Mar; 11(1):6168. PubMed ID: 33731764
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
Lewis SJ; Mueller BA
J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
